In the annual Research Round Up series, Cancer.Net Editorial Board members answer the questions, “What was the most exciting or practice-changing research in your field presented at the 2021 ASCO Annual Meeting, and what does it mean for people with cancer?” In this webinar, Cancer.Net Specialty Editors Neeraj Agarwal, MD; Petros Grivas, MD, PhD; Tian Zhang, MD, MHS; and Timothy Gilligan, MD, FASCO, discuss new and ongoing research in prostate cancer, bladder cancer, kidney cancer, and testicular cancer.
-
A Medicare database analysis evaluated how often standard of care therapies for metastatic castration-sensitive prostate cancer were being used in real-world treatment from 2009 to 2018, particularly among racial minorities. [3:07]
-
Results from the TITAN phase III clinical trial, which showed whether adding apalutamide (Erleada) to hormonal therapy impacted quality of life in people with metastatic castration-sensitive prostate cancer. [8:14]
-
Findings from the VISION phase III clinical trial, which was studying whether adding a new type of radiation therapy to the standard of care for people with metastatic castration-resistant prostate cancer stopped cancer growth and helped them live longer. [11:15]
-
An analysis of the subgroups from the JAVELIN Bladder 100 phase III clinical trial evaluated whether adding maintenance immunotherapy using avelumab (Bavencio) to supportive care after chemotherapy for people with advanced bladder cancer helped all patients or only certain subgroups of patients live longer. [14:57]
-
Updated results after 5 years of follow-up from the KEYNOTE-052 phase II clinical trial, which showed whether treatment with the immunotherapy pembrolizumab (Keytruda) helped shrink the tumors of people with advanced bladder cancer who could not receive cisplatin-based chemotherapy. [19:43]
-
Updated results after 5 years of follow-up from the KEYNOTE-045 phase III clinical trial, which evaluated whether pembrolizumab helped people live longer if they have recurrent, advanced bladder cancer that progressed after platinum-based chemotherapy. [24:15]
-
Findings from the KEYNOTE-564 phase III clinical trial, which was studying whether pembrolizumab delayed recurrence if it was given to people with high-risk clear cell kidney cancer following surgery to remove the tumor. [26:22]
-
Updated results after 3 and a half years of follow-up from the KEYNOTE-426 phase III clinical trial, which was evaluating whether the combination of pembrolizumab and the targeted therapy axitinib (Inlyta) stopped cancer growth for people with advanced clear cell kidney cancer and helped them live longer. [28:11]
-
An analysis from the CLEAR phase III clinical trial showed whether treatment with the targeted therapy lenvatinib (Lenvima) and pembrolizumab improved quality of life for people with advanced kidney cancer compared with treatment with sunitinib (Sutent) alone. [29:48]
-
Results from a phase I/II clinical trial testing whether treating people with MET-driven, metastatic papillary kidney cancer using a combination of the targeted therapies savolitinib (AZD6094, HMPL-504, volitinib) and durvalumab (Imfinzi) helped shrink the cancer. [32:18]
-
An analysis of cancer registry data in Norway showed that people who are cured of testicular cancer using radiation therapy and/or chemotherapy had a higher risk of dying from causes other than testicular cancer compared with individuals in the general population. [33:28]
-
Results from the SEMS phase II clinical trial, which was evaluating whether surgery using retroperitoneal lymph node dissection (RPLND) could be an alternative to chemotherapy or radiation therapy for people with early metastatic seminoma. [36:52]
Dr. Agarwal is the senior director of clinical research innovation at the Huntsman Cancer Institute at the University of Utah and is a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Grivas is the clinical director of the Genitourinary Cancers Program at University of Washington Medicine, an associate member of the clinical research division at the Fred Hutchinson Cancer Research Center, and a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Zhang is an associate professor of medicine at Duke University School of Medicine, a medical oncologist at Duke Cancer Institute, and a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Gilligan is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute and a Cancer.Net Specialty Editor for Genitourinary Cancers.
Disclosure information for this webinar’s speakers can be found in their individual biographies, which are linked in the paragraph above.
Cancer.Net podcasts are edited for length and content.
Was this webinar useful? Please subscribe, rate, and review Cancer.Net Podcasts wherever you listen to podcasts. This prerecorded webinar can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.
